Newsletter Signup - Under Article / In Page
"*" indicates required fields
Aberdeen, we say goodbye to you!
We’re leaving Scotland this week and are heading down to Belgium. Besides being the place where most of the European Union action happens, Belgium also has a strong and interesting biotech scene. That’s why in Namur we’re visiting VolitionRx, our Biotech of the Week.
City: Namur (Belgium)
Founded: 2010
Employees: 11-50 employees
Financial Data: €77M
CEO: Cameron Reynolds
Mission: VolitionRx wants to address the need for non-invasive, accurate, and cost-effective diagnostics for cancer and other conditions.
Founded in 2010, VolitionRx brings together ELISA diagnostics (a long established method to identify proteins) with cutting-edge nucleosome detection and analysis techniques.
The resulting test takes less than a drop of blood and can measure and analyze nucleosomes (a basic unit of ‘packed’ DNA), which are often irregular in diseases like cancer.
Comment: The market cap of VolitionRx is over €78M, which is quite big for a diagnostics-focused biotech.
Blood-based diagnostics are a definite trend (see the discussion of Eva Diagnostics at Labiotech Refresh), and VolitionRx’s technology looks really exciting.